Neglected Disease Research and Development: Reflecting on a Decade of Global Investment
Each year since 2007, the G-FINDER project has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development (R&D) of new products to prevent, diagnose, control or cure neglected diseases in developing countries. It provides an up-to-date analysis of how R&D investments are being allocated across diseases and product types, funding trends over time, and where the potential gaps lie.
This is the tenth annual G-FINDER report. In addition to the previous nine years of funding data, it reports on investments made in financial year 2016. In all, 187 organisations completed the survey for FY2016, which covered 33 neglected diseases and all relevant product types: drugs, vaccines (preventive and therapeutic), diagnostics, microbicides and vector control products (pesticides, biological control agents and vaccines targeting animal reservoirs) – as well as basic research.
In 2016, following a review by the G-FINDER Advisory Committee, the bacterial pneumonia & meningitis category was expanded to include developing country-focused basic research for both Streptococcus pneumoniae and/or Neisseria meningitidis. Developing country-specific research into therapeutic vaccines for HIV/AIDS was also added as a restricted category.
While included in the last two G-FINDER reports, analysis of R&D funding for African viral haemorrhagic fevers (including Ebola) was separated from the neglected disease funding analysis in 2016. A separate scope definition has been developed to identify investments in R&D for all priority emerging infectious diseases identified in the World Health Organization R&D Blueprint for action to prevent epidemics. EID data is not included in this G-FINDER neglected disease report, and will be reported separately.
Visit the Policy Cures website to learn more about the G-Finder reports.